Search research articles
Contact Us
Filters
Showing results (81-90 of 102) with videos related to
Page
of 11
Sort By:
Journal of the National Cancer Institute
|
May 13, 2014
Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma
Ahmed O Kaseb, Lianchun Xiao, Manal M Hassan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2024
The Landscape of ctDNA in Appendiceal Adenocarcinoma
Michael G White, Mohammad A Zeineddine, Eleanor A Fallon, et al.
NPJ Precision Oncology
|
February 13, 2023
Survival improvement for patients with metastatic colorectal cancer over twenty years
Fadl A Zeineddine, Mohammad A Zeineddine, Abdelrahman Yousef, et al.
The Lancet. Oncology
|
November 18, 2022
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Funda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2022
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Benny Johnson, Cara L Haymaker, Edwin R Parra, et al.
Cancer Research Communications
|
November 16, 2022
Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer
Van K Morris, Michael J Overman, Michael Lam, et al.
The Lancet. Oncology
|
August 8, 2024
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
Kanwal Raghav, Salvatore Siena, Atsuo Takashima, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 3, 2019
Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma
Awalpreet S Chadha, Jillian R Gunther, Cheng-En Hsieh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
Manish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Journal of Hepatocellular Carcinoma
|
March 10, 2021
Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy
Brian De, Sweet Ping Ng, Amy Y Liu, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 102) with videos related to
Sort By:
Page
of 11
Journal of the National Cancer Institute
|
May 13, 2014
Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma
Ahmed O Kaseb, Lianchun Xiao, Manal M Hassan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2024
The Landscape of ctDNA in Appendiceal Adenocarcinoma
Michael G White, Mohammad A Zeineddine, Eleanor A Fallon, et al.
NPJ Precision Oncology
|
February 13, 2023
Survival improvement for patients with metastatic colorectal cancer over twenty years
Fadl A Zeineddine, Mohammad A Zeineddine, Abdelrahman Yousef, et al.
The Lancet. Oncology
|
November 18, 2022
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Funda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2022
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Benny Johnson, Cara L Haymaker, Edwin R Parra, et al.
Cancer Research Communications
|
November 16, 2022
Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer
Van K Morris, Michael J Overman, Michael Lam, et al.
The Lancet. Oncology
|
August 8, 2024
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
Kanwal Raghav, Salvatore Siena, Atsuo Takashima, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 3, 2019
Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma
Awalpreet S Chadha, Jillian R Gunther, Cheng-En Hsieh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
Manish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Journal of Hepatocellular Carcinoma
|
March 10, 2021
Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy
Brian De, Sweet Ping Ng, Amy Y Liu, et al.
Page
of 11